loading

Dyne Therapeutics Inc (DYN) 最新ニュース

pulisher
Apr 16, 2025

More C-suite changes at Dyne - biocentury.com

Apr 16, 2025
pulisher
Apr 15, 2025

Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | DYN Stock News - GuruFocus

Apr 15, 2025
pulisher
Apr 15, 2025

Dyne Therapeutics (DYN) Enhances Leadership Team with Key Appoin - GuruFocus

Apr 15, 2025
pulisher
Apr 15, 2025

Dyne Therapeutics Announces Chief Business Officer and Chief Sci - GuruFocus

Apr 15, 2025
pulisher
Apr 15, 2025

Dyne Therapeutics reshapes leadership team ahead of drug launches - Investing.com

Apr 15, 2025
pulisher
Apr 15, 2025

Dyne Therapeutics Announces Chief Business Officer and Chief Scientific Officer Appointments - GlobeNewswire

Apr 15, 2025
pulisher
Apr 15, 2025

Strategic C-Suite Expansion: Dyne Therapeutics Gears Up for Rare Disease Drug Launches - Stock Titan

Apr 15, 2025
pulisher
Apr 14, 2025

Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Apr 14, 2025
pulisher
Apr 14, 2025

Dyne Therapeutics Reveals Strategic Compensation Plan: 330K Stock Options Granted - Stock Titan

Apr 14, 2025
pulisher
Apr 11, 2025

Dyne wins new Outperform at BMO on prospects for lead drug - MSN

Apr 11, 2025
pulisher
Apr 10, 2025

Insider Purchases Worth US$1.06m See Losses As Dyne Therapeutics Market Value Drops To US$770m - Yahoo Home

Apr 10, 2025
pulisher
Apr 07, 2025

Myotonic Dystrophy Pipeline Analysis and Clinical Trials - openPR.com

Apr 07, 2025
pulisher
Apr 03, 2025

RBC Cuts Price Target on Dyne Therapeutics to $36 From $41, Keeps Outperform, Speculative Risk - MarketScreener

Apr 03, 2025
pulisher
Apr 02, 2025

FORCE platform boosts muscle function in dystrophic mice - BioWorld MedTech

Apr 02, 2025
pulisher
Apr 01, 2025

Oversold Conditions For Dyne Therapeutics - Nasdaq

Apr 01, 2025
pulisher
Apr 01, 2025

FORCE platform leads to Duchenne muscular dystrophy mouse model - BioWorld MedTech

Apr 01, 2025
pulisher
Mar 26, 2025

BMO maintains Dyne Therapeutics stock with $50 target By Investing.com - Investing.com Canada

Mar 26, 2025
pulisher
Mar 24, 2025

MDA 2025: DYNE-101 improves finger function in DM1 clinical trial - Muscular Dystrophy News

Mar 24, 2025
pulisher
Mar 21, 2025

Dyne names Editas’ Erick Lucera CFO - biocentury.com

Mar 21, 2025
pulisher
Mar 21, 2025

JPMorgan Seeks Clarity On Dyne Therapeutics' DYNE-101 Expansion, Regulatory Path - Benzinga

Mar 21, 2025
pulisher
Mar 21, 2025

Sector Update: Health Care Stocks Steady Premarket Friday -March 21, 2025 at 09:24 am EDT - Marketscreener.com

Mar 21, 2025
pulisher
Mar 21, 2025

JPMorgan cuts Dyne Therapeutics stock target to $17 from $18 By Investing.com - Investing.com Canada

Mar 21, 2025
pulisher
Mar 21, 2025

Dyne Therapeutics Announces Appointment of Erick J. Lucera as Chief Financial Officer - The National Law Review

Mar 21, 2025
pulisher
Mar 20, 2025

Dyne Therapeutics Appoints Erick Lucera as Chief Financial Officer - citybiz

Mar 20, 2025
pulisher
Mar 20, 2025

Dyne Therapeutics names new CFO ahead of clinical milestones By Investing.com - Investing.com South Africa

Mar 20, 2025
pulisher
Mar 20, 2025

Dyne Therapeutics Names Erick Lucera as CFO -March 20, 2025 at 05:36 pm EDT - Marketscreener.com

Mar 20, 2025
pulisher
Mar 20, 2025

Dyne Therapeutics Appoints Erick Lucera as CFO - TipRanks

Mar 20, 2025
pulisher
Mar 20, 2025

Dyne Therapeutics Announces Appointment of Erick J. Lucera As Chief Financial Officer - Marketscreener.com

Mar 20, 2025
pulisher
Mar 20, 2025

Dyne Therapeutics names new CFO ahead of clinical milestones - Investing.com

Mar 20, 2025
pulisher
Mar 20, 2025

Dyne Therapeutics Reports Inducement Grants Under Nasdaq - GlobeNewswire

Mar 20, 2025
pulisher
Mar 20, 2025

New Dyne Therapeutics CFO Secures Major Equity Package Worth 280,600 Shares - StockTitan

Mar 20, 2025
pulisher
Mar 20, 2025

Dyne Therapeutics Strengthens Commercial Launch Plans With Strategic CFO Appointment - StockTitan

Mar 20, 2025
pulisher
Mar 20, 2025

(DYN) Technical Data - news.stocktradersdaily.com

Mar 20, 2025
pulisher
Mar 20, 2025

Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Financial Officer - The Globe and Mail

Mar 20, 2025
pulisher
Mar 18, 2025

Dyne reports new long-term data from Phase 1/2 DELIVER trial of DYNE-251 - MSN

Mar 18, 2025
pulisher
Mar 17, 2025

Stifel maintains Buy on Dyne Therapeutics with $66 target By Investing.com - Investing.com Canada

Mar 17, 2025
pulisher
Mar 17, 2025

H.C. Wainwright maintains $46 target on Dyne Therapeutics stock By Investing.com - Investing.com Canada

Mar 17, 2025
pulisher
Mar 17, 2025

H.C. Wainwright maintains $46 target on Dyne Therapeutics stock - Investing.com

Mar 17, 2025
pulisher
Mar 17, 2025

Dyne Therapeutics Says Trial of Potential Duchenne Muscular Dystrophy Drug Shows 'Meaningful' Results - MarketScreener

Mar 17, 2025
pulisher
Mar 17, 2025

Dyne Therapeutics (DYN) Gets a Buy from Scotiabank - The Globe and Mail

Mar 17, 2025
pulisher
Mar 16, 2025

Dyne Therapeutics Announces New Long-Term Clinical Data - GlobeNewswire

Mar 16, 2025
pulisher
Mar 16, 2025

Dyne : Phase 1/2 Trial Of DYNE-251 In DMD Shows Sustained Functional Improvements Through 18 Months - Nasdaq

Mar 16, 2025
pulisher
Mar 16, 2025

Dyne Therapeutics Announces New Long-Term Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented and Sustained Functional Improvement Through 18 Months - The Manila Times

Mar 16, 2025
pulisher
Mar 16, 2025

Dyne Therapeutics Reports Promising Long-Term Data for DYNE-251 in Duchenne Muscular Dystrophy with Plans for Accelerated Approval Submission - Nasdaq

Mar 16, 2025
pulisher
Mar 15, 2025

Dyne Therapeutics, Inc. (NASDAQ:DYN) Given Average Rating of “Buy” by Brokerages - Defense World

Mar 15, 2025
pulisher
Mar 14, 2025

BMO Capital Markets Begins Coverage on Dyne Therapeutics (NASDAQ:DYN) - Defense World

Mar 14, 2025
pulisher
Mar 13, 2025

Dyne therapeutics chief commercial officer sells $1,733 in stock By Investing.com - Investing.com Australia

Mar 13, 2025
pulisher
Mar 13, 2025

Dyne therapeutics chief commercial officer sells $1,733 in stock - Investing.com

Mar 13, 2025
pulisher
Mar 13, 2025

Dyne Therapeutics chief scientific officer sells shares worth $24,501 By Investing.com - Investing.com South Africa

Mar 13, 2025
pulisher
Mar 13, 2025

Dyne Therapeutics chief scientific officer sells shares worth $24,501 - Investing.com

Mar 13, 2025
pulisher
Mar 13, 2025

GDX Is Looking To Retest 2020 Highs; Gold To 3K Soon? - The Globe and Mail

Mar 13, 2025
pulisher
Mar 13, 2025

Dyne: Accelerated Approval DYNE-101 Might Be Possible With Surrogate Biomarker (DYN) - Seeking Alpha

Mar 13, 2025
$20.04
price up icon 2.51%
$72.65
price up icon 3.49%
$32.60
price up icon 1.27%
$24.61
price up icon 6.77%
$98.76
price up icon 0.52%
biotechnology ONC
$230.98
price up icon 1.24%
大文字化:     |  ボリューム (24 時間):